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Prostate cancerCell adhesion and migration play important roles in physiological and pathological states, including embryonic
development and cancer invasion andmetastasis. The type I transmembrane proteinwith epidermal growth fac-
tor and two follistatin motifs 2 (TMEFF2) is expressed mainly in brain and prostate and its expression is
deregulated in prostate cancer. We have previously shown that TMEFF2 can function as a tumor suppressor by
inhibiting cell migration and invasion of prostate cells. However, the molecular mechanisms involved in this in-
hibition are not clear. In this study we demonstrate that TMEFF2 affects cell adhesion and migration of prostate
cancer cells and that this effect correlates with changes in integrin expression and RhoA activation. Deletion of a
13 basic-rich amino acid region in the cytoplasmic domain of TMEFF2 prevented these effects. Overexpression of
TMEFF2 reduced cell attachment and migration on vitronectin and caused a concomitant decrease in RhoA acti-
vation, stress ﬁber formation and expression ofαv,β1 and β3 integrin subunits. Conversely, TMEFF2 interference
in 22Rv1 prostate cancer cells resulted in an increased integrin expression. Results obtained with a double
TRAMP/TMEFF2 transgenic mouse also indicated that TMEFF2 expression reduced integrin expression in the
mouse prostate. In summary, the data presented here indicate an important role of TMEFF2 in regulating cell ad-
hesion and migration that involves integrin signaling and is mediated by its cytoplasmic domain.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Prostate cancer is themost commonly diagnosed cancer and the sec-
ond leading cause of cancer deaths in American men [1]. While organ-
conﬁned prostate cancer is successfully treated by surgical methods,
no curative treatment is available for themetastatic form of the disease,
which is responsible for themortality associatedwith this disease. Pros-
tate cancer cells are known tometastasize to numerous organs,with the
bone, liver, and lymph nodes being themost common [2]; however, the
molecular mechanisms that drive the metastatic cascade in prostate
cancer are poorly understood. Understanding these mechanisms and
the molecules involved in the metastatic cascade is critical to develop-
ing strategies for maximizing the efﬁcacy of prostate cancer treatment.the National Cancer Institute
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chevarría).Integrins are members of a family of transmembrane glycoprotein
receptors that mediate cell–cell and the interactions with the extracel-
lular matrix (ECM) [3]. By interacting with cytoskeletal-associated pro-
teins, integrins provide a link between the extracellular environment
and the cytoskeleton inside the cells. Integrins are heterodimers com-
posed of non-covalently associated α and β subunits that can recognize
and bind multiple ECM ligands, triggering a variety of signal transduc-
tion events thatmodulate diverse cellular processes including prolifera-
tion, survival, gene expression, adhesion and migration [3,4]. Evidence
of altered integrin signaling has been demonstrated in several types of
cancer, including prostate cancer. These changes correlate with tumor
growth, invasion, and metastatic potential [5,6].
Several integrins,α2β1,α3β1,α5β1,α6β1,αvβ1,αIIbβ3, andαvβ3
are expressed in prostate cancer cells [6,7]. Of those,αvβ3 and β1 seem
to play important roles in bone metastases, the main site of metastatic
prostate cancer [7–9]. While not typically expressed in epithelial cells
[8], integrin αvβ3 is expressed in prostate cancer. Its expression corre-
lates with disease progression, metastatic potential [5–8], and with
prostate cancer cell adhesion to vitronectin, a major extracellular com-
ponent of mature bone [10]. Integrin β1 is upregulated in specimens
fromprostate cancer patients, and antibodies againstβ1 integrins inhib-
it binding of PC3 prostate cancer cells to human bonemarrow endothe-
lial cells [7,11], suggesting that β1 integrin mediates bone metastasis.
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out signaling) can promote a conformational change in the integrin that
lead to higher afﬁnity for its ligand [12–14]. Ligand binding (outside-in
signaling) ultimately leads to integrin activation and clustering into
large mature focal adhesions (FAs) which generate downstream signal-
ing events in a temporal fashion [12,15]. One of the changes that takes
place early following integrin activation is the cytoskeletal rearrange-
ments that regulate stress ﬁber formation and promote cell spreading
and initiation of migration [16]. These events involve integrin-
mediated modulation of speciﬁc cellular kinases and of RhoA activi-
ty [14,17]. RhoA is essential to remodeling actin ﬁbers, regulation of ac-
tomyosin contractility, and rear cell detachment during motility [18].
RhoA is also activated via G-protein coupled receptors (GPCRs) that
couple to the heterotrimeric G12/13 proteins, highlighting a coopera-
tive relationship between integrin and GPCR signaling. Cross talk has
also been described between integrins and growth factor receptor sig-
naling to affect cell spreading, migration, growth and survival [19,20].
TMEFF2 is an evolutionarily conserved type I transmembrane pro-
tein expressed in the embryo, and selectively in the adult brain and
prostate [21–23]. A role for TMEFF2 in prostate cancer was suggested
by studies indicating that TMEFF2 expression is altered in a signiﬁcant
fraction of primary andmetastatic prostate tumors [22,23].We have de-
scribed that TMEFF2 functions as a tumor suppressor, and that this role
correlates, at least in part, with its ability to interact with SARDH to
modulate cellular levels of sarcosine [24]. TMEFF2 overexpression
blocked basal and sarcosine-induced cellular invasion of prostate epi-
thelial RWPE cells, while TMEFF2 knockdown in 22Rv1 prostate cancer
cells promoted increased cellular migration/invasion [25]. While these
results highlight a role for TMEFF2 in the invasion of prostate cells, the
molecular mechanism(s) involved in this process are not known. Here
we report that TMEFF2 expression inhibits spreading and migration of
RWPE2 prostate cancer cells on vitronectin. This inhibition correlates
with a defect in FA and stress ﬁber formation and in RhoA activation
and requires the presence of the cytoplasmic tail of TMEFF2. Important-
ly, TMEFF2 downregulates the expression of several integrins in RWPE2
cells indicating that themotility effects observed are integrin-mediated.
The results presented point to an important role of TMEFF2 inmodulat-
ing integrin signaling and prostate cell motility.
2. Materials and methods
2.1. Cell culture and plasmids
The 22Rv1, RWPE1 and RWPE2 cell lines were purchased from
American Type Culture Collection (ATCC, Manassas, VA). The human
prostate epithelial cell line RWPE1 and its Ki-ras transformed tumori-
genic derivative, RWPE2, were cultured in KSF medium (Invitrogen,
Carlsbad, CA). The human prostate carcinoma cell line 22Rv1wasmain-
tained in RPMI-1640 medium (Invitrogen, Carlsbad, CA). TMEFF2 full
length and ΔGA expression constructs were previously described [24,
26]. The development of a system for inducible expression of
FL_TMEFF2 and TMEFF2_ΔGA in RWPE2 cells was achieved using the
Clontech's Tet-On Advanced system (Clontech, Mountain View, CA)
essentially as described before for RWPE1 cells [24]. To inducibly ex-
press TMEFF2, cultures were grown in the presence of doxycycline
(250 ng/ml; Sigma, St. Louis, MO). 22Rv1 cells transduced with pLKO.1
vectors containing shRNA to TMEFF2 or scramble control were de-
scribed before [25].
2.2. Reagents
Antibodies recognizing TMEFF2 from cell lysates were purchased
from Abcam (Cambridge, MA) and Sigma (St. Louis, MO). For TMEFF2
detection from mouse tissue lysates a SDIX, custom antibody was uti-
lized (SDIX, Newark, DE). Other antibodies utilized in this study are:
SV40 T-antigen (Abcam; Cambridge, MA), ITGAV, ITGB1 and ITGB3(BD Biosciences, Franklin Lakes, NJ), ITGB3 (for mouse tissue lysates,
Sigma, St. Louis, MO), ITGA5 (Millipore, Billerica, MA), ribosomal pro-
tein S6, β-actin, phospho-FAK, and FAK (Cell Signaling, Danvers, MA).
Antibodies used for the immunoﬂuorescence studies are listed in
Section 2.5. The U0126 MAPK inhibitor or the inactive analog U0124
was purchased from Sigma (St. Louis, MO). Bovine serum albumin
(BSA) was from Sigma (St. Louis, MO).
2.3. Mice
Animals were maintained in accordance with the Institutional Ani-
mal Care and Use Committee of East Carolina University. Transgenic
TMEFF2mice (129/Sv background, Lineberger Cancer Center Transgenic
mouse facility) were crossed and maintained in a C57BL/6 background
(backcrossed for over seven generations to C57BL/6). TRAMP mice
(FVB background) were purchased from the Jackson laboratory (Bar
Harbor, ME; stock number 008215) and crossed to C57Bl/6J (stock
number 000664). The F1 generation derived from this cross, was then
crossed to the transgenic TMEFF2 mouse and the TRAMP/TMEFF2 and
the TRAMPprogenywere selected after genotyping by PCR using tail ge-
nomic DNA. The TRAMP mice were genotyped as speciﬁed by the
Jackson Laboratory (BarHarbor,ME). The TMEFF2micewere genotyped
using primers 5′-GGAATTGCTCTGGTTATGATG-3′ and 5′-CAAATGTGGT
ATGGCTGATTATG-3′.
2.4. Cell migration assays
Cell migration was measured using either a wound healing assay
or Boyden chambers. Both assays were performed in the presence of
1 μg/ml aphidicolin (Sigma, St. Louis, MO) to prevent proliferation. For
wound healing assays, 70 μl of cells (from a 3 to 7 × 105 cells/ml suspen-
sion) was loaded into each well of a culture plate insert (ibidi, Verona,
WI). After 24 h incubation, the insert was removed to allow cell migra-
tion into the wound. Wound healing process was monitored by taking
pictures at 0, 10, 24, or 48 h after removal of the insert, using an EVOS
FL cell imaging system (Life Technologies, Carlsbad, CA). When speci-
ﬁed, 2 μg/ml of CT04 (Cytoskeleton, Denver, CO) was added to the
fresh medium after insert removal.
Cell migration was also assayed using Boyden chambers with non-
coated 8 μM pore size membranes (BD Biosciences, Franklin Lakes, NJ).
Cells (5 × 104) were suspended in 200 μl of serum-free medium and
loaded into the upper chamber. The lower chamber was ﬁlled with
500 μl of medium supplemented with 20% fetal bovine serum (FBS;
Life Technologies, Carlsbad, CA) that was used as a chemoattractant.
After 20 h of incubation, the cells that hadmigrated to the lower surface
of the membrane were ﬁxed with 70% ethanol for 10 min, followed
by staining with 0.1% crystal violet (Sigma, St. Louis, MO) and photo-
graphed. To assay cell migration towards vitronectin or ﬁbronectin the
following modiﬁcations were implemented: i) the lower surface of the
membrane in the Boyden chambers was treated with 10 μg/ml of the in-
dicated ECMproteins or BSA as control (prepared in PBS) for 16 h at 4 °C;
ii) cells (0.5–1 × 104) were suspended in 200 μl of KSF base medium and
loaded into the upper chamber; iii) the lower chamber was also ﬁlled
with KSF medium; and iv) the culture was maintained for 1–2 days.
2.5. Cell spreading assay and immunoﬂuorescence
Round cover glass slips (Fisher Scientiﬁc, Hampton, NH) were coat-
edwith collagen (40 μg/ml; BD Biosciences, Franklin Lakes, NJ), laminin
(10 μg/ml; Sigma, St. Louis, MO), ﬁbronectin (40 μg/ml; Millipore,
Billerica, MA), or vitronectin (2 μg/ml; Promega, Fitchburg, WI) by incu-
bation at 4 °C overnight and rinsed twice with PBS. Once coated, the
cover glass slips were placed inside the wells of 12-well culture plates
and 40,000 cells were loaded onto each well. Following 3 h incubation,
pictures were taken for 10 random ﬁelds for each cover glass using an
EVOS FL cell imaging system (Life Technologies, Carlsbad, CA) and
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wereﬁxedwith 4%paraformaldehyde in PBS (AffymetrixUSB, Cleveland,
OH) for 10 min, permeabilized with 0.5% Triton X-100 (Bio-Rad, Hercu-
les, CA) in PBS (PBS-T) for 5 min, and blocked with 5% normal goat
serum in PBS-T for 30 min. Samples were then incubated with anti-
vinculin antibody (Sigma, St. Louis, MO) at 4 °C overnight followed by
goat anti-mouse Alexa Fluor 488 (Invitrogen, Carlsbad, CA) and rhoda-
mine phalloidin (Cytoskeleton, Denver, CO) for 1 h. Nuclei were counter-
stained with DAPI (Santa Cruz Biotechnology, Santa Cruz, CA). For
immunoﬂuorescence analysis with rhodamine phalloidin only staining,
cells were seeded in 8 well glass chamber slides (Lab-Tek, Scotts Valley,
CA) and the primary antibody and the corresponding secondary anti-
body were omitted. Immunoﬂuorescent images were taken on an
Optiphot-2 ﬂuorescent microscope (Nikon) with an AxioCamMRm dig-
ital camera (Zeiss).
2.6. G-LISA RhoA activation assay
Cells were incubated in serum free EpiLife CF/PRF medium
(Invitrogen, Carlsbad, CA) for 3 d and then stimulated with 10% FBS
for 2 min. RhoA activity was determined using a colorimetric G-LISA
RhoA Activation Assay Biochem kit (Cytoskeleton, Denver, CO) accord-
ing to the manufacturer's instructions.
2.7. Western blotting
Western blot analysis was conducted as described before [24] using
cell lysates or lysates from individual mouse prostate lobes. Brieﬂy, cells
were lysed in radioimmunoprecipitation assay (RIPA) buffer containing
50 mM Tris–HCl (pH 7.4), 150 mM sodium chloride, 1% Triton X-100,
0.5% sodium deoxycholate, 0.1% SDS, protease inhibitor cocktail (Sigma,
St. Louis, MO), sodium orthovanadate and beta-glycerophosphate.
Lobes were lysed in the same buffer using a glass homogenizer. Equal
amounts of proteins were resolved by SDS-PAGE and transferred to
Immobilon transfer membrane (Millipore, Billerica, MA). Blots were
blocked in 5% non-fat milk or bovine serum albumin (BSA; Sigma, St.
Louis, MO) and probedwith the appropriate antibodies. Immunoreactive
bands were visualized using SuperSignalWest Pico or Femto chemilumi-
nescent substrate (Thermo Scientiﬁc, Waltham, MA).
2.8. RT2 proﬁler PCR array
The Human Focal Adhesion RT2 Proﬁler PCR Array (SABiosciences,
Valencia, CA) was used to determine cellular adhesion-related gene ex-
pression affected by TMEFF2 according to the manufacturer's instruc-
tions. Brieﬂy, total RNA was extracted from cells expressing TMEFF2 or
the vector, as a control, with RNeasymini kit and cDNAwas synthesized
with RT2 First Strand Kit (Qiagen, Valencia, CA). The cDNA was com-
bined with RT2 SYBR Green Mastermix (Qiagen, Valencia, CA) and dis-
pensed into the RT2 Proﬁler PCR Array. Real-time PCR was performed
on an iQ5 instrument (Bio-Rad, Hercules, CA).
2.9. Statistical analysis
Data are presented as mean ± SD. Student's t test (paired, two-
tailed) was used to compare two groups of independent samples.
P values under 0.05 or 0.01 were considered signiﬁcant.
3. Results
3.1. The cytoplasmic domain of TMEFF2 is necessary for its tumor
suppression role
The transmembrane and cytoplasmic domains of TMEFF1 and
TMEFF2, the two members of the TMEFF family of proteins, are very
well conserved at the amino acid level, and contain potential GPCR-signaling motifs in the membrane and cytoplasmic domains [27]. For
TMEFF1, the relevance of these domains is underscored by data pointing
to different functions of the protein depending on their presence [28].
TMEFF2 overexpression in prostate epithelial RWPE1 cells inhibits the
intrinsic and sarcoine-induced migration potential of these cells [24]. To
examine the role of the TMEFF2 cytoplasmic domain, we used a deletion
mutant lacking 13 consecutive basic-rich amino acids in the C-terminus
of the protein (TMEFF2_ΔGA). Full length TMEFF2 (FL_TMEFF2) or
TMEFF2_ΔGA was expressed in RWPE1 and RWPE2 cells and their effect
on cell migration was analyzed. Expression of the different forms of
TMEFF2 was achieved using cell lines that express FL_TMEFF2 or
TMEFF2_ΔGA under the control of a doxycycline-inducible promoter
(Fig. 1A andB). Control cellswere transducedwith the transactivator con-
struct only (vector).
Results obtained using a wound-healing assay indicated that, as op-
posed to cells expressing the full length TMEFF2 protein, RWPE1 or
RWPE2 cells expressing the TMEFF2_ΔGA protein did not signiﬁcantly
show inhibition of migration when compared with cells transfected
with the vector control only (Fig. 1C, D and Supplementary Fig. S1A).
Similar results were obtained using Boyden chambers (Supplementary
Fig. S1B). These results suggest that the cytoplasmic tail of TMEFF2 is
necessary for its ability to inhibit migration of prostate epithelial and
cancer cells. Interestingly, a tendency towards slower migration was
observed in cells expressing TMEFF2_ΔGA when compared with cells
expressing the vector control. This may reﬂect more than one mecha-
nism to inhibit migration. All together these results suggest that the cy-
toplasmic tail of TMEFF2 is important for its tumor suppressor function.
It is worth noting that while in RWPE2 cells the expression of the
TMEFF2_ΔGAmutant seems lower than expression from the FL_TMEFF2,
variable levels of expression have been frequently observed from exper-
iment to experiment and this does not seem to be the reason why
TMEFF2_ΔGA does not have an effect on migration. In fact, as shown in
Fig. 1A, the expression level of the FL_TMEFF2 and TMEFF2_ΔGA was
similar in RWPE1 cells but the TMEFF2_ΔGA did not affect migration in
this cell line.
3.2. TMEFF2 promotes cell rounding and reduces cell spreading
In order for cells to migrate they must attach and spread. In these
studies we observed that TMEFF2 promotes cell rounding of RWPE2
and several other cell lines (Fig. 2A and not shown), suggesting defec-
tive attachment and spreading of TMEFF2 expressing cells, perhaps ac-
counting for the inhibitory effect of TMEFF2 on migration. To test this
hypothesis, attachment/spreading to tissue culture plates of RWPE2
cells expressing the inducible FL_TMEFF2, or TMEFF2_ΔGA, or the vec-
tor control, was examined. As shown in Fig. 2B,when grown in the pres-
ence of doxycycline to induce FL_TMEFF2 expression, a two-fold
increase in the number of round cells was observed when compared
to cells expressing the empty vector or the TMEFF2_ΔGA. These round-
ed cells had few lamellipodia protrusions (Fig. 2C), indicating that the
initial stages of spreading were affected. Cell attachment/spreading
to plates coated with the ECM proteins vitronectin, ﬁbronectin, laminin
and collagen type I was also analyzed. RWPE2 cells expressing the
empty vector control or the TMEFF2_ΔGA behaved similarly, with
over 90% of cells attaching/spreading to ﬁbronectin and collagen type
I and 80–85% to vitronectin and laminin (Fig. 3A). However, when
compared to cells expressing the empty vector or the TMEFF2_ΔGA, ex-
pression of FL_TMEFF2 signiﬁcantly reduced the ability of cells to at-
tach/spread on the vitronectin coated surface (only 58% of the cells;
Fig. 3A). This suggests that TMEFF2 blocks spreading on vitronectin
coated surfaces, and this could ultimately affect migration. Further,
results obtained using a transwell assay, indicated that migration
of RWPE2 cells expressing FL_TMEFF2 was signiﬁcantly reduced
in vitronectin but not in ﬁbronectin, when compared to cells expressing
TMEFF2_ΔGA or the empty vector control (Fig. 3B). Migration towards
BSA coated transwell membranes was negligible independent of
Fig. 1. TMEFF2 inhibits migration in RWPE1 and RWPE2 cells. A, B) Cells were grown in the presence of 250 ng/ml doxycycline to induce the expression of FL_TMEFF2 or TMEFF2_ΔGA.
Overexpression of these proteins in RWPE1 (A) and RWPE2 (B) cells after doxycycline treatment was assessed by western blot. The slow mobility band corresponds to a previously de-
scribed highly glycosylated form of the protein [22]. The reasonwhy this from is over-representedwhen the TMEFF2_ΔGAmutant is expressed is not clear. C, D) Cell migration of RWPE1
(C) or RWPE2 (D) cells expressing the different forms of TMEFF2,was determined using awound healing assay, 48 (RWPE1) or 10h (RWPE2) after thewoundwasmade. Quantiﬁcation of
relative migration (fold over the vector) is presented as mean ± SD of three independent experiments.
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TMEFF2 inhibits attachment/spreading on vitronectin and that this in-
hibitory effect requires the presence of the cytoplasmic tail.
3.3. TMEFF2 reduces stress ﬁber and focal adhesion formation and
activation
Since the presence of focal adhesions (FAs) correlates with cell at-
tachment and spreading [29] the ability of FL_TMEFF2 to inhibit the
formation of these macromolecular structures was examined.
RWPE2 cells expressing FL_TMEFF2, or TMEFF2_ΔGA, or the empty
vector control were grown on cover glass coated with ﬁbronectin
or vitronectin and stained with rhodamine-phalloidin to detect poly-
merized actin and vinculin antibodies to detect FA. As described
above, expression of FL_TMEFF2, but not the mutant lacking the cy-
toplasmic tail, resulted in an increase in rounded cells when cells
were grown on vitronectin. These rounded cells revealed a cortical
actin cytoskeleton, without stress ﬁbers, and a lack of FAs as demon-
strated by diffuse vinculin staining (Fig. 4A; middle row). Converse-
ly, the normal attachment/spreading of FL_TMEFF2 expressing
RWPE2 cells to ﬁbronectin correlated with stress ﬁber formation
and the presence of FA at the ends of the ﬁbers (Fig. 4A, Supplemen-
tary Fig. S2). Expression of the TMEFF2_ΔGA mutant, did not affect
stress ﬁber or FA formation when grown on either vitronectin or ﬁ-
bronectin (Fig. 4A bottom row) when compared to cells expressing
the vector control (Fig. 4A, upper row). Finally, phosphorylation of
focal adhesion kinase (FAK) at tyrosine 397 (Y397) was analyzed
by western blot. FAK phosphorylation is required for FA formationand cell migration. The results, shown in Fig. 4B, indicated that
FL_TMEFF2 but not TMEFF2_ΔGA inhibited FAK-Y397 phosphorylation.
All together these results indicate that TMEFF2 interferes with FA for-
mation/activation and, as a consequence, it inhibits cell spreading and
migration. The cytoplasmic tail of TMEFF2 is required for these effects.
3.4. TMEFF2 inhibits RhoA activation
RhoA activation promotes stress ﬁber formation and maturation of
focal adhesions. Since the results obtained indicated that expression of
TMEFF2 affects these processes, the ability of TMEFF2 to affect RhoA ac-
tivation was examined. Rho is active in the GTP-bound state, which is
catalyzed by the Dbl family of guanine nucleotide exchange factors
(GEFs) [30]. The amount of activated RhoA was determined using the
G-LISA kit in RWPE2 cells expressing the different forms of TMEFF2
and compared to the activity of cells expressing the vector as control.
Cells were grown in serum-free media and then stimulated with fetal
bovine serum (FBS). The results indicated that TMEFF2 expression sig-
niﬁcantly reduced the level of active RhoA to 78% of that in the control
cells (Fig. 5). RhoA activity in cells expressing TMEFF2_ΔGA did not dif-
fer signiﬁcantly from either the FL_TMEFF2 expressing or the empty
vector control expressing cells. Changes in RhoA activation correlated
with the formation of stress ﬁbers, since expression of FL_TMEFF2, but
not TMEFF2_ΔGA, also inhibited stress ﬁber formation (Fig. 5). These re-
sults indicate that TMEFF2 decreases RhoA activation in FBS-stimulated
conditions and this may in part be mediated by the cytoplasmic tail of
TMEFF2. Since RhoA plays a role in migration, it is possible that the ob-
served TMEFF2-mediated inhibition of migration is, at least partly, due
Fig. 2. TMEFF2 inhibits RWPE2 cell spreading on tissue culture plates. A) Representative images of cellmorphology of RWPE2 cells expressing different forms of the TMEFF2 protein, or the
empty vector, on tissue culture surface. Arrows point to rounded cells. Scale bars, 100 μm. B) Quantiﬁcation of round cells at 3 h after seeding 40,000 cells/well in a 12-well plate. Data are
presented asmean± SDof three independent experiments. C) Representative images of cellmorphology of RWPE2 cells expressing the inducible FL_TMEFF2 before and after the addition
of doxycycline. Note that FL_TMEFF2 expression promotes cell rounding and those cells lack lamellipodia.
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cells with CT04, a Rho inhibitor, dramatically reduced stressﬁber forma-
tion and inhibited cellular migration by 50% (Supplementary Fig S3A).
3.5. TMEFF2 modulates expression of integrins in part through the MAPK
pathway
Integrins are the main ECM receptors. They are involved in motility
and migration, and integrin signaling can modulate RhoA activation
[17]. To determine whether the effect of TMEFF2 on migration and
RhoA activation is mediated by an effect on integrin levels, changes in
the expression of a subset of integrins in response to TMEFF2 were an-
alyzed. The human extracellularmatrix and adhesionmolecule RT2 pro-
ﬁler PCR array was used to investigate differences in expression of 21
different integrin subunits (15 α and 6 β) – other genes important for
cell–cell and cell–matrix interactions are also included in the array –
in RWPE2 cells. Expression of FL_TMEFF2 but not TMEFF2_ΔGA in
RWPE2 cells reduced the levels of some integrin's mRNA, including
αv, β1 and β3 (Supplementary Fig. S4). For those integrins, the ob-
served decrease in mRNA levels corresponded with a decrease in total
protein levels as measured by western blot (Fig. 6A). Expression of
these integrins was also analyzed in 22Rv1/sh_TMEFF2 cells [25], in
which expression of endogenous TMEFF2 is reduced by sh_RNA, and
in 22Rv1/sh_scramble control cells. As shown in Fig. 6A, decreasing
the level of TMEFF2by sh_RNApromoted an increase in integrinαv pro-
tein levels. Expression of the β1 and β3 integrins was not detected in
these cells (Fig. 6A and data not shown). These results demonstrate
that FL_TMEFF2 inhibits the expression of the αv, β1 and β3 integrins,
and that the cytoplasmic tail is required for this inhibition. Attempts
to rescue the effect on migration mediated by TMEFF2 by transientlyoverexpressingαv and β3 integrins failed. However, these experiments
are complicated by the large number of integrins that appear to be
affected by TMEFF2 (see Supplementary Fig. S4) and the rather promis-
cuous function of the integrins [31].
Since we have previously demonstrated that TMEFF2 modulates
MAPK signaling in response to growth factors [26], the possibility that
TMEFF2 affects integrin expression through this pathway was exam-
ined. RWPE2 cells expressing FL_TMEFF2 or the empty vector as a con-
trol, were treated with the U0126 MAPK inhibitor or with U0124, a
chemical analog that does not haveMAPK inhibitory activity, and the ef-
fect on integrin expression was determined. As shown in Fig. 6B, in the
presence of the inactive analog U0124, expression of TMEFF2 resulted in
a decrease in integrin β3 level thatwas less pronounced in the presence
of U0126 — fourfold difference. No effect was observed in the level of
integrin αv (data not shown). Western blot analysis with antibodies
against phosphorylated ERK indicated that U0126 inhibited the MAPK
pathway. There was not a signiﬁcant inhibition observed with U0124.
While the effect of TMEFF2 on integrin expression was not fully
abolished by U0126, these results indicate that MAPK signaling plays a
role in the modulation of integrin expression by TMEFF2.
3.6. TMEFF2 expression inhibits integrin expression in vivo
In humans TMEFF2 is expressed mainly in brain and prostate, how-
ever, TMEFF2 is not expressed in the adult mouse prostate [23]. We
have generated a transgenic TMEFF2 mouse model that expresses
TMEFF2 driven by the probasin promoterwith transgene expression re-
stricted to the prostate (Supplementary Fig. S5). As described for the
probasin promoter expression pattern [32], TMEFF2 is expressed more
in the ventral (VP) and dorsolateral (DLP) prostate with almost no
Fig. 3. Effect of TMEFF2 in different ECM substrates. A) TMEFF2 signiﬁcantly inhibits cell spreading on vitronectin-coated surfaces. RWPE2 cells expressing FL_TMEFF2, or TMEFF2_ΔGA, or
the vector control were plated onto cover glass coatedwith the different ECM substrates. Percentages of spread cells were analyzed 3 h after seeding. Data are presented as mean± SD of
ﬁve independent experiments. B) TMEFF2 inhibits RWPE2 cellmigration towards vitronectin but notﬁbronectin asmeasured in a Boyden chamber assay. Shown are representative images
of RWPE2 cells expressing the different TMEFF2 constructs after 48 h migration (top), and quantiﬁcation of those images by densitometric analysis using ImageJ (bottom). Data are pre-
sented as mean ± SD of three independent experiments.
Fig. 4. TMEFF2 reduces stress ﬁber and focal adhesion formation and activation. A) RWPE2 cells expressing FL_TMEFF2, or TMEFF2_ΔGA, or the vector control were cultured on cover glass
coated with ﬁbronectin or vitronectin for 3 h and then stained with anti-vinculin (green), rhodamine phalloidin (orange), and DAPI (blue). Scale bar, 20 μm. B) Immunoblotting of phos-
phorylated FAK (Y397), FAK and β-actin (ACTB) in RWPE2 cells. Numbers under the western blots represent the densitometry quantiﬁcations using ImageJ.
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Fig. 5. TMEFF2 inhibits Rho activation. RWPE2 cells expressing FL_TMEFF2, or
TMEFF2_ΔGA, or the vector control were incubated in serum-free EpiLife CF/PRF medium
for 3 days and then stimulated with 10% FBS for 2 min. Levels of GTP-bound RhoA were
determined by G-LISA RhoA activation assays. Data are presented asmean± SD of ﬁve in-
dependent experiments (top). Rhodamine phalloidin staining of the cells stimulatedwith
10% FBS for 10min (bottom) demonstrating the lack of stress ﬁbers in the cells expressing
FL_TMEFF2. Scale bar, 25 μm.
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mentary Fig. S5; Overcash, RF and Ruiz-Echevarria, MJ, unpublished ob-
servations). The TMEFF2 transgenic animals were crossed to a mouse
model of prostate cancer designated TRAMP (transgenic adenocarcino-
ma of mouse prostate) and 15 weeks TMEFF2/TRAMP and TRAMP sib-
lings were selected for the analysis of integrin expression. After
euthanasia, the prostates were dissected and protein lysates from the
anterior, ventral and dorsolateral lobes were prepared and analyzed
for the expression of αv, β3 and β1 integrin subunits by western blot
analysis. β1 integrin has been previously shown to be upregulated in
the TRAMP mouse [33]. As shown in Fig. 6C, as compared with the
TRAMP model, expression of TMEFF2 in the TRAMP mouse led to re-
duced expression of theαv, β1 and β3, integrins indicating that expres-
sion of TMEFF2 reduces integrin expression in vivo. Changes in the level
of the α5 integrin subunit were not observed, as it was the case in the
prostate cell lines tested.
4. Discussion
Cell migration is an essential step in embryogenesis as well as in the
development ofmetastatic lesions during cancer progression.While the
metastatic process is not fully understood, enhanced migration on ex-
tracellular matrix (ECM) substrates correlates with increased metasta-
sis. Here we present data to show that TMEFF2, a transmembrane
proteinwith limited expression to embryo and adult brain and prostate,
plays a role in cellular adhesion andmigration bymodulating activation
of the small GTPase RhoA, and/or integrin expression.
In this study, we demonstrated that expression of TMEFF2 in pros-
tate cancer cells, or in prostate lobes of a TRAMP/TMEFF2 transgenic
mouse, signiﬁcantly reduced the expression of at least three integrin
subunits, αv, β3 and β1. In agreement with this, we observe that
TMEFF2 inhibits prostate cancer cell migration in vitronectin; αvβ3 is
the major receptor for vitronectin. Importantly, in vitro and in vivo ex-
periments have demonstrated that expression of αvβ3 plays anessential role in the metastasis of prostate cancer to bone, accounting
for more than 80% of prostate cancer metastases [2]. The αvβ3 integrin
plays numerous roles in prostate cancer metastasis. By modulating en-
graftment and survival after bone colonization tumor cell expression
of this integrin is critical to the success of metastatic lesions. Expressed
also in osteoclasts, αvβ3 is also critical to bone resorption and the met-
astatic growth of the tumor in the bone [9]. Similar results have been
observed in breast cancer where expression ofαvβ3 in amammary car-
cinoma line thatmetastasizes to the lung, but not to bone, was sufﬁcient
to promote its spontaneous metastasis to bone [34,35]. Expression of
αvβ3 has also been associated with metastasis to lungs [36]. Interest-
ingly, preliminary data from our laboratory indicates that formation of
metastasis to lungs is reduced in the double TRAMP/TMEFF2 transgenic
when compared with the TRAMP mouse (not shown), suggesting that
TMEFF2 inhibits metastasis by affecting integrin expression. The results
presented here also indicated that TMEFF2 affects expression of the β1
integrin. Interestingly, it has been reported that β1 integrin deletion in
a TRAMPmouse increases prostate epithelial cell differentiation and re-
sults inmore aggressive tumorswhile having no effect on the frequency
of metastases, as determined by visual inspection [37]. Conversely, in
our TRAMP/TMEFF2 transgenic animal, in which expression of β1 and
other integrins is reduced, we do not observe changes in the latency
or grade of the tumors but in the occurrence and number of metastases
(Overcash RF. and Ruiz-Echevarria MJ., unpublished observations). It is
possible that this reﬂects differences in the balance of integrin heterodi-
mer formation. Interestingly, it has recently been reported that inactiva-
tion of integrin β1 promotes expression of β3 in malignant cells,
enhancing metastatic progression [38]. Based on these results, the fact
that TMEFF2 reduces the levels of integrins β1 and β3 could provide
an explanation to the phenotypic differences observed between the
TRAMP mouse with a deletion of integrin β1 and the TRAMP/TMEFF2
transgenic animals.
In prostate cancer cells, expression of TMEFF2 affects cellularmigra-
tion and invasion [24, 25, and this study]. Overexpression of TMEFF2
inhibited the migration of RWPE1 and RWPE2 cells. Conversely, inter-
ference of TMEFF2 expression in prostate cancer 22Rv1 cells promoted
increased migration/invasion. Interestingly, the invasive ability of
22Rv1 cells in which expression of TMEFF2 was reduced, was highly
susceptible to the anti-folate drug methotrexate [25] suggesting that
one-carbon availability is central to the migration/invasion phenotype
mediated by changes in TMEFF2. Based on these results, it is reasonable
to speculate that TMEFF2, by affecting one carbon metabolism, may af-
fect expression of integrin genes epigenetically, via methylation. Al-
though we have not directly tested that hypothesis, several studies
have described epigenetic alterations – DNA methylation and histone
modiﬁcations – that affect integrin expression during tumor progres-
sion [39,40].
The role of TMEFF2 in prostate cancer is complex, and while the full
lengthmembrane bound form functions as a tumor suppressor, a soluble
shed form of TMEFF2, the ectodomain, promotes growth [24]. This has
led to the hypothesis that the predominant form of TMEFF2, and there-
fore its role, change as the disease progresses [24,26,41]. It is likely that
the full length and the TMEFF2 ectodomain differentially affect integrin
expression during disease progression. We have previously demonstrat-
ed that TMEFF2 affects Akt and/or ERK activation so that the full-length
activates ERK but has no effect on Akt phosphorylation while the
ectodomain inhibits ERK phosphorylation concomitantlywith Akt activa-
tion in response to growth factors [26]. The results presented here sug-
gest that TMEFF2 modulates integrin expression, in part via the MAPK
pathway. Other mechanisms need to be identiﬁed. Since integrins have
been shown to induce Akt [42,43] and ERK phosphorylation [44], it is
also possible that TMEFF2modulatesMAPK and PI3K pathways via its ef-
fects on integrin expression establishing a negative feedback loop. This
would suggest that TMEFF2 may modulate the cross-talk between
integrins and growth factor receptors to control cellular responses includ-
ing survival, growth, differentiation and migration. In this respect, it is
Fig. 6. TMEFF2modulates the abundance ofαv, β1 and β3 integrins in cell lines and inmouse prostates. A) Total lysates of the indicated cell lines were subjected to immunoblotting with
antibodies against the integrins as shown. Note that TMEFF2 did not promote changes inα5 integrin levels and that 22Rv1 cells do not express β3 integrin. B) Total lysates of RWPE2 cells
treatedwith 10 μMMAPK inhibitor U0126 or inactive analog U0124 for 24 hwere subjected to immunoblotting with integrin β3 antibody. The effectiveness ofMAPK inhibitionwas dem-
onstrated using an antibody against phosphorylated ERK. C) Tissue lysates from the anterior (A), ventral (V) or dorsolateral (DL) lobes of the mouse prostate were subjected to immuno-
blotting with antibodies against the speciﬁed integrins. Arrows indicate the sizes of the individual integrin subunits observed in cell lines. Additional bands may represent precursor
proteins, which are also decreased by TMEFF2. β-Tubulin (TUBB) or ribosomal protein S6 (RPS6) were used as a loading controls. Numbers under the western blots are the densitometry
quantiﬁcations of the arrow-pointed bands normalized to the loading control using ImageJ. Note that the complexity of the banding pattern for the β3 integrin inmouse prostate lobes did
not allow quantiﬁcation however, the decrease in the abundance as a result of TMEFF2 expression is clear.
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only regulated by growth factors but also by functional collaboration
with integrins, and integrins may activate RTKs in the absence of growth
factors [19,45].
In this study we have demonstrated that expression of TMEFF2 re-
sulted in decreased RhoA activation and stress ﬁber formation and
that the latter effectwas also dependent on the presence of an intact cy-
toplasmic domain of TMEFF2. Based on a predicted homology of this do-
main with G-protein couple receptors (GPCRs), initially plausible
hypothesis is that TMEFF2maymodulate RhoA activation by, for exam-
ple, restricting the function of GPCRs that are involved in Gα12/13 or
Gαq activation which induce Rho [46], or by promoting the activity of
the Rho inhibitory Gαz signaling [47]. If this were the case, TMEFF2
would control migration via two independent mechanisms since RhoA
inactivation does not seem to affect integrin expression (Supplementa-
ry Fig. S3B). While we have not formally ruled out this possibility, the
fact that integrins can control the activation of Rho-GTPases, either by
engaging Src-tyrosine kinases, or via crosstalkwith growth factor recep-
tor signaling, suggests an alternativemechanism bywhich TMEFF2may
also control RhoA activation by controlling integrin expression and thus,
cell spreading andmigration. It is known, that by regulating the balancebetween Rac1-mediated membrane protrusion and RhoA-mediated
contractility, integrins control cytoskeletal-dependent processes in-
volved in cell adhesion and spreading and therefore cell movement
and migration [17,48].
In summary, these results demonstrate that TMEFF2 negatively reg-
ulates cell adhesion and migration to the ECM by affecting integrin ex-
pression and RhoA activation, and suggest a potentially important role
for TMEFF2 as a metastasis inhibitor.
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